ViiV opens up brand-new HIV med Tivicay for cheap copies in poor countries

HIV drug specialist ViiV Healthcare has tossed a brand-new product into the Medicines Patent Pool. ViiV--a joint venture of GlaxoSmithKline ($GSK), Pfizer ($PFE) and Shionogi--inked a deal with MPP to speed access to cheap copies of Tivicay (dolutegravir) in developing countries. Among the pricier HIV treatments, Tivicay was FDA-approved last year, and analysts figure it could hit $5 billion in sales. Report

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.